We are live on ! Find out more
UBIO

Proshares UltraPro NASDAQ Biotechnology
UBIO

Delisted

UBIO was delisted on the 27th of March, 2020.

Back to rankings

7 hedge funds and large institutions have $3.23M invested in Proshares UltraPro NASDAQ Biotechnology in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,001% more capital invested

Capital invested by funds: $293K → $3.23M (+$2.93M)

75% more funds holding

Funds holding: 4 → 7 (+3)

10.13% more ownership

Funds ownership: 1.48% → 11.6% (+10%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
2
Closed
–
Calls
$435K
Puts
–
Net Calls
+$435K
Net Calls Change
+$439K

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$1.5M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$903K
3
CG
Cutler Group
California
+$40.4K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$235K
2
UBS Group
UBS Group
Switzerland
-$186

UBIO Hedge Fund Activity: Q4 2019 in Review

7 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q4 2019, worth a combined $3.23M — up 1,001% from $293K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new UBIO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $1.5M. The largest seller was Tower Research Capital (TRC), cutting an estimated $235K.

  • 7 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q4 2019, up from 4 in Q3 2019.
  • Funds reported $3.23M of Proshares UltraPro NASDAQ Biotechnology stock for Q4 2019, up 1,001% quarter-over-quarter.
  • 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q4 2019 and 0 closed out, a net change of +3 holders.
  • The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q4 2019 was Jane Street, an estimated $1.5M added.
  • The largest Proshares UltraPro NASDAQ Biotechnology seller in Q4 2019 was Tower Research Capital (TRC), an estimated $235K sold.

Based on aggregated 13F filings for Q4 2019.